Crosscope partners with Farcast Biosciences to reshape the precision oncology landscape

This partnership will help researchers to collaborate, centrally review, facilitate training, image viewing & analysis, and at the same time be used to improve the assessment of standard pathological features

with an aim to reshape the precision oncology landscape via AI-powered pathology, Crosscope, Silicon Valley-based provider of Vendor Agnostic AI-enabled Digital Pathology Platform, and Farcast Bioscience, a Florida based Company has announced their collaboration.

Farcast has developed a human tumor histoculture platform that can preserve the entire architecture of the human tumor microenvironment. The two companies will work together for the prospective evaluation of OrionAI-AI-based diagnostic assistant for histological examination of a variety of solid tumors beginning with Head and Neck Squamous Cell Carcinoma (HNSCC) Cancer. HNSCC is the most prevalent cancer in India and both companies have decided to enter into a collaboration to tackle a disease that presents a unique healthcare challenge for India. This partnership will help researchers to collaborate, centrally review, facilitate training, image viewing & analysis, and at the same time be used to improve the assessment of standard pathological features.

By augmenting the capacity of pathologists, Crosscope and Farcast aim to accelerate the speed of diagnosis significantly reducing turnaround times (TAT) and bring down the rate of misdiagnosis by leveraging the digitisation of pathology. 

The main objective of this collaboration is to assess the ability of Crosscope’s deep learning technology to detect and quantify the major tumor pathology hallmarks from digitised H&E slides and study their correlation and accuracy when compared with trained pathologists’ assessment.